Gottlieb Defends Accelerated Approval, Scorns Access Limits By Payors

US FDA's accelerated approval pathway is more reliable and has better validated biomarkers than a decade ago, commissioner says, arguing coverage limits on AA products are not in the interest of public health.

MedicineUnderAMicroscope_1200x675

US FDA Commissioner Scott Gottlieb is defending the accelerated approval pathway in response to payors who have balked at covering high-priced products cleared under what they perceive to be a lower regulatory standard than the traditional approval process.

Speaking during the National Organization for Rare Disorders’ “Rare Summit” on Oct. 17, Gottlieb acknowledged “some instances” in which payors...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards